Medicine and Dentistry
Patient
100%
Phase II Trials
66%
Therapeutic Procedure
66%
Lymphoma
50%
Doxorubicin
50%
Cyclophosphamide
50%
Spontaneous Remission
33%
Toxicity
33%
Methotrexate
33%
Bone Marrow
33%
Oncology
33%
Diseases
16%
Dexamethasone
16%
Serum
16%
Follow up
16%
Bleomycin
16%
Overall Survival
16%
Vincristine
16%
Fatality
16%
Folinic Acid
16%
Lactate Dehydrogenase
16%
Granulocytopenia
16%
Arm
16%
Survival
16%
Pharmacology, Toxicology and Pharmaceutical Science
Lymphoma
50%
Doxorubicin
50%
Cyclophosphamide
50%
Toxicity
33%
Remission
33%
Methotrexate
33%
Diseases
16%
Dexamethasone
16%
Overall Survival
16%
Vincristine
16%
Fatality
16%
Bleomycin
16%
Granulocytopenia
16%
Lactate Dehydrogenase
16%
Folinic Acid
16%
Survival
16%
Immunology and Microbiology
Cyclophosphamide
50%
Methotrexate
33%
Dose
33%
Dexamethasone
16%
Overall Survival
16%
Granulocytopenia
16%
Lactate Dehydrogenase Blood Level
16%
Survival
16%
Arm
16%